132 related articles for article (PubMed ID: 12412827)
1. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir.
Perloff MD; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 2002 Nov; 42(11):1269-74. PubMed ID: 12412827
[TBL] [Abstract][Full Text] [Related]
2. Transport characteristics of fexofenadine in the Caco-2 cell model.
Petri N; Tannergren C; Rungstad D; Lennernäs H
Pharm Res; 2004 Aug; 21(8):1398-404. PubMed ID: 15359574
[TBL] [Abstract][Full Text] [Related]
3. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
4. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.
Störmer E; von Moltke LL; Perloff MD; Greenblatt DJ
Pharm Res; 2002 Jul; 19(7):1038-45. PubMed ID: 12180537
[TBL] [Abstract][Full Text] [Related]
5. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein interactions of nefazodone and trazodone in cell culture.
Störmer E; von Moltke LL; Perloff MD; Greenblatt DJ
J Clin Pharmacol; 2001 Jul; 41(7):708-14. PubMed ID: 11452702
[TBL] [Abstract][Full Text] [Related]
7. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line.
Perloff MD; Von Moltke LL; Marchand JE; Greenblatt DJ
J Pharm Sci; 2001 Nov; 90(11):1829-37. PubMed ID: 11745741
[TBL] [Abstract][Full Text] [Related]
8. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters.
Ming X; Knight BM; Thakker DR
Mol Pharm; 2011 Oct; 8(5):1677-86. PubMed ID: 21780830
[TBL] [Abstract][Full Text] [Related]
9. Transport characteristics of ebastine and its metabolites across human intestinal epithelial Caco-2 cell monolayers.
Imamura Y; Shimizu K; Yamashita F; Yamaoka K; Takakura Y; Hashida M
Biol Pharm Bull; 2001 Aug; 24(8):930-4. PubMed ID: 11510488
[TBL] [Abstract][Full Text] [Related]
10. Rapid assessment of P-glycoprotein inhibition and induction in vitro.
Perloff MD; Störmer E; von Moltke LL; Greenblatt DJ
Pharm Res; 2003 Aug; 20(8):1177-83. PubMed ID: 12948015
[TBL] [Abstract][Full Text] [Related]
11. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
12. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo.
Shi J; Cao B; Zha WB; Wu XL; Liu LS; Xiao WJ; Gu RR; Sun RB; Yu XY; Zheng T; Li MJ; Wang XW; Zhou J; Mao Y; Ge C; Ma T; Xia WJ; Aa JY; Wang GJ; Liu CX
Acta Pharmacol Sin; 2013 Oct; 34(10):1349-58. PubMed ID: 23892274
[TBL] [Abstract][Full Text] [Related]
14. Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers.
Hosoya KI; Kim KJ; Lee VH
Pharm Res; 1996 Jun; 13(6):885-90. PubMed ID: 8792427
[TBL] [Abstract][Full Text] [Related]
15. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells.
Gao J; Murase O; Schowen RL; Aubé J; Borchardt RT
Pharm Res; 2001 Feb; 18(2):171-6. PubMed ID: 11405287
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
Pauli-Magnus C; von Richter O; Burk O; Ziegler A; Mettang T; Eichelbaum M; Fromm MF
J Pharmacol Exp Ther; 2000 May; 293(2):376-82. PubMed ID: 10773005
[TBL] [Abstract][Full Text] [Related]
18. The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers - An in vitro and in vivo comparison.
Weinheimer M; Fricker G; Burhenne J; Mylius P; Schubert R
Eur J Pharm Sci; 2017 Oct; 108():13-22. PubMed ID: 27590127
[TBL] [Abstract][Full Text] [Related]
19. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure.
Perloff MD; von Moltke LL; Störmer E; Shader RI; Greenblatt DJ
Br J Pharmacol; 2001 Dec; 134(8):1601-8. PubMed ID: 11739235
[TBL] [Abstract][Full Text] [Related]
20. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
Yasui-Furukori N; Uno T; Sugawara K; Tateishi T
Clin Pharmacol Ther; 2005 Jan; 77(1):17-23. PubMed ID: 15637527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
